250 related articles for article (PubMed ID: 30837996)
1. Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance.
Han P; Dai Q; Fan L; Lin H; Zhang X; Li F; Yang X
Front Immunol; 2019; 10():251. PubMed ID: 30837996
[TBL] [Abstract][Full Text] [Related]
2. USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis.
Li M; Xu Y; Liang J; Lin H; Qi X; Li F; Han P; Gao Y; Yang X
Mol Ther; 2021 Jun; 29(6):2108-2120. PubMed ID: 33601053
[TBL] [Abstract][Full Text] [Related]
3. Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy.
Zhang X; Cheng C; Sun W; Wang H
Methods Mol Biol; 2020; 2115():419-433. PubMed ID: 32006414
[TBL] [Abstract][Full Text] [Related]
4. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.
Freeman AJ; Vervoort SJ; Ramsbottom KM; Kelly MJ; Michie J; Pijpers L; Johnstone RW; Kearney CJ; Oliaro J
Cell Rep; 2019 Sep; 28(11):2784-2794.e5. PubMed ID: 31509742
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
6. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
Potts MA; McDonald JA; Sutherland KD; Herold MJ
Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
[TBL] [Abstract][Full Text] [Related]
7. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
8. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
9. Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies.
Nüssing S; House IG; Kearney CJ; Chen AXY; Vervoort SJ; Beavis PA; Oliaro J; Johnstone RW; Trapani JA; Parish IA
J Immunol; 2020 Apr; 204(8):2308-2315. PubMed ID: 32152070
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer.
Azangou-Khyavy M; Ghasemi M; Khanali J; Boroomand-Saboor M; Jamalkhah M; Soleimani M; Kiani J
Front Immunol; 2020; 11():2062. PubMed ID: 33117331
[TBL] [Abstract][Full Text] [Related]
11. Generation of Cancer-Specific Cytotoxic PD-1
Lu S; Yang N; He J; Gong W; Lai Z; Xie L; Tao L; Xu C; Wang H; Zhang G; Cao H; Zhou C; Zhong L; Zhao Y
J Biomed Nanotechnol; 2019 Mar; 15(3):593-601. PubMed ID: 31165703
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
13. Identification of essential genes for cancer immunotherapy.
Patel SJ; Sanjana NE; Kishton RJ; Eidizadeh A; Vodnala SK; Cam M; Gartner JJ; Jia L; Steinberg SM; Yamamoto TN; Merchant AS; Mehta GU; Chichura A; Shalem O; Tran E; Eil R; Sukumar M; Guijarro EP; Day CP; Robbins P; Feldman S; Merlino G; Zhang F; Restifo NP
Nature; 2017 Aug; 548(7669):537-542. PubMed ID: 28783722
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas9 system: A new-fangled dawn in gene editing.
Gupta D; Bhattacharjee O; Mandal D; Sen MK; Dey D; Dasgupta A; Kazi TA; Gupta R; Sinharoy S; Acharya K; Chattopadhyay D; Ravichandiran V; Roy S; Ghosh D
Life Sci; 2019 Sep; 232():116636. PubMed ID: 31295471
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
Liu W; Yang C; Liu Y; Jiang G
Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function.
Shifrut E; Carnevale J; Tobin V; Roth TL; Woo JM; Bui CT; Li PJ; Diolaiti ME; Ashworth A; Marson A
Cell; 2018 Dec; 175(7):1958-1971.e15. PubMed ID: 30449619
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
19. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
Ghaffari S; Khalili N; Rezaei N
J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
